AOD 9604: What Researchers Need to Know

AOD 9604 Research: Understanding the Modified Growth Hormone Fragment

AOD 9604 (Anti-Obesity Drug 9604) is a modified peptide fragment corresponding to amino acids 177-191 of human growth hormone, with the addition of a tyrosine residue at the N-terminus. Developed at Monash University in Australia by Professor Frank Ng and colleagues, AOD 9604 research has focused on understanding how this specific region of the growth hormone molecule interacts with metabolic pathways independently of the full-length hormone and its growth-promoting effects.

Aureum Peptides provides research-grade AOD 9604 at 99%+ purity for qualified laboratory investigations.

Molecular Profile and Design Rationale

Human growth hormone (hGH) is a 191-amino-acid protein with diverse biological activities mediated through different structural domains. Research in the 1990s identified that the C-terminal region (amino acids 177-191) appeared to be associated with lipid metabolism effects, while growth-promoting and diabetogenic effects mapped to other regions of the molecule.

AOD 9604 was designed to isolate the C-terminal metabolic activity from the full-length hormone. The addition of the N-terminal tyrosine was incorporated to stabilize the peptide structure. The resulting 16-amino-acid peptide retains a disulfide bond between Cys residues (corresponding to Cys182-Cys189 in full-length hGH) that is essential for its three-dimensional conformation and biological activity in research models.

Published Research Findings

AOD 9604 research has generated several key findings in preclinical models:

• Lipolytic pathway activation: Studies have demonstrated AOD 9604 stimulates lipolysis in adipose tissue models through a mechanism that appears distinct from full-length growth hormone signaling (Ng et al., 2000).
• Beta-3 adrenergic receptor interaction: Research suggests AOD 9604 may interact with beta-3 adrenergic receptor pathways, which are expressed primarily in adipose tissue and are involved in lipid mobilization (Heffernan et al., 2001).
• Lipogenesis inhibition: In vitro studies using adipocyte cell lines have reported AOD 9604 effects on de novo lipogenesis (new fat synthesis) pathways, suggesting dual activity on both fat breakdown and fat storage mechanisms.
• IGF-1 independence: Unlike full-length GH, AOD 9604 research has not demonstrated significant effects on IGF-1 levels or insulin sensitivity markers in studied models, supporting the rationale of its fragmentary design.

Mechanisms Under Investigation

Adipose Tissue Specificity: A central question in AOD 9604 research is how a fragment of growth hormone can exhibit tissue-specific metabolic effects without the broader endocrine consequences of the full-length hormone. Researchers are examining whether AOD 9604 interacts with a distinct binding site or receptor subtype on adipocytes that differs from the classical GH receptor.

Signal Transduction: While full-length GH signals primarily through JAK2-STAT5 pathways, AOD 9604 does not appear to activate this canonical signaling cascade. Research is ongoing to characterize the specific intracellular pathways engaged by the C-terminal fragment.

Chondrocyte Research: More recently, AOD 9604 has been investigated in cartilage biology models. Some studies have explored its effects on chondrocyte proliferation and proteoglycan synthesis, expanding its research applications beyond metabolic studies.

Research Protocol Considerations

• Store lyophilized AOD 9604 at -20 degrees C, protected from light and moisture
• Reconstitute in sterile water or bacteriostatic water
• Adipocyte differentiation assays (3T3-L1 cells) are commonly used research models
• Lipolysis can be measured via glycerol release assays or free fatty acid quantification
• The disulfide bond is essential for activity — avoid reducing conditions during handling
• Working concentrations in published cell culture studies range from nanomolar to low micromolar

Quality Standards for Metabolic Research

Metabolic research assays are sensitive to compound quality. Every batch of AOD 9604 from Aureum Peptides undergoes HPLC purity analysis and mass spectrometry verification to confirm molecular identity and disulfide bond integrity. Access full analytical data through our COA verification portal or learn about our testing methodology.

Browse our complete research peptide catalog for additional compounds relevant to metabolic research.